CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

3D-Bioprinted Platform For Comprehensive Cell Analysis

3D-Bioprinted Platform For...

Significance of Bioanalytical Services

Significance of Bioanalytical Services

Enhancing Bioanalytical Workflows with Latest Technology

Enhancing Bioanalytical Workflows...

How Remote Monitoring can Improve Healthcare Delivery?

How Remote Monitoring can Improve...

What You Should Know About Bioanalytical Method Validation

What You Should Know About...

What are Some Popular Applications of Analytical Testing Techniques?

What are Some Popular Applications of...

The Role of Technology in Transforming Bioanalysis

The Role of Technology in...

What You Should Know Bioanalytical Method Validation

What You Should Know Bioanalytical...

3D-Bioprinted Platform For Comprehensive Cell Analysis

3D-Bioprinted Platform For...

Significance of Bioanalytical Services

Significance of Bioanalytical Services

Enhancing Bioanalytical Workflows with Latest Technology

Enhancing Bioanalytical Workflows...

How Remote Monitoring can Improve Healthcare Delivery?

How Remote Monitoring can Improve...

What You Should Know About Bioanalytical Method Validation

What You Should Know About...

What are Some Popular Applications of Analytical Testing Techniques?

What are Some Popular Applications of...

The Role of Technology in Transforming Bioanalysis

The Role of Technology in...

What You Should Know Bioanalytical Method Validation

What You Should Know Bioanalytical...

Forbion Announces its New General Partner

Life Sciences Review | Wednesday, June 16, 2021
Tweet

Bos led a team of twenty-one investment professionals at M Ventures, which invested 400 million euros in over 50 portfolio companies ranging from biotech to life sciences tools to IT, with investment activities ranging from seed to cross-over and IPO.


FREMONT, CA: Forbion, a leading European life sciences venture capital firm, announced the addition of Jasper Bos, Ph.D., a former Merck executive, as General Partner for the firm's Growth Fund. Bos was Senior Vice President and Managing Director of M Ventures, the venture arm of pharmaceutical major Merck, before joining Forbions' Naarden headquarters in 2009. He led a team of twenty-one investment professionals at M Ventures, which invested 400 million euros in over 50 portfolio companies ranging from biotech to life sciences tools to IT, with investment activities ranging from seed to cross-over and IPO.


"In light of the recent, sizable final close, at the EUR 360 million hard cap of our Forbion Growth Opportunities Fund I, we are pleased to have a seasoned life sciences investment professional like Jasper joining our growing team. Jasper has overseen four companies through their IPO process, and has vast experience with pharma spin-outs and prominent licensing deals involving diverse stakeholders from big-pharma to leading academic institutions. 


His scientific and financial experience will be instrumental as we continue implementing our strategy which is to enable the most innovative companies bring new impactful treatments and therapies to market," explained Sander Slootweg, Managing Partner, Forbion.


Commenting on his appointment as General Partner, Jasper Bos added, "I am excited to be joining Forbion, in my view one of the leading investment firms in the life sciences space, and to actively contribute to deploying their Growth Opportunities Fund and thus help to grow the market for late-stage European biotech investing in Europe. I look forward to working with the Forbion team, and I am confident that my track record in the industry will be complementary to theirs, especially when it comes to creating pharma spin outs."


Bos has previously worked with the Netherlands Vaccine Institute, the Dutch National Institute of Public Health, and private equity firms. He graduated from the University of Groningen in the Netherlands with a doctorate in pharmacy.


Weekly Brief

loading
Top 10 Bioanalytical Service Companies in Europe - 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/forbion-announces-its-new-general-partner-nwid-399.html